Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005988 · ClinicalTrials.gov registry record · Phase 1
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
A Phase 1 study of Lymphoma and Leukemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT00005988 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00005988, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the donor bone marrow with the patient's white blood cells and a monoclonal antibody may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of bone marrow transplantation with specially treated bone marrow in treating patients who have hematologic cancer that has not responded to previous therapy.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG methylprednisolone
- DRUG leucovorin calcium
- DRUG methotrexate
- DRUG cyclosporine
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- University of Minnesota Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2000-02 |
| Est. Completion | 2002-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005988
The ClinicalTrials.gov registry entry for NCT00005988 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005988 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00005988 about?
NCT00005988 is a clinical study titled "Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy". RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the donor bone marrow with the pa...
What is the current status of trial NCT00005988?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2000-02. Estimated completion is 2002-03-08.
What conditions does trial NCT00005988 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Graft-Versus-Host Disease, Myeloma.
What interventions are being tested in trial NCT00005988?
The interventions under investigation include: cyclophosphamide (DRUG), methylprednisolone (DRUG), leucovorin calcium (DRUG), methotrexate (DRUG), cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00005988?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005988 being conducted?
This trial has 2 study locations across Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.